Presence of D110 antigen expressing immunocompetent cells in glioblastoma associates with prolonged survival

Neuropathology and Applied Neurobiology

Volumn 30, Issue 6, 2004, Pages 608-614

  Preusser, M ^a   Strobel T ^a   Birner, P ^b   Marosi, C ^b   Dieckmann, K ^b   Rossler K ^b   Budka, H ^a   Lassmann, H ^b   Hainfellner, Johannes A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cancer immunology; Dendritic cell; Glioblastoma; Immunotherapy; Microglia; Prognosis

Indexed keywords

ANTIGEN; CD68 ANTIGEN; D110 ANTIGEN; DACARBAZINE; FOTEMUSTINE; HLA DR ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LOMUSTINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D110; NIMUSTINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ANTIBODY LABELING; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LANGERHANS CELL; MACROPHAGE; MAJOR CLINICAL STUDY; MICROGLIA; MONOCYTE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; SURVIVAL; TISSUE INJURY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; COHORT STUDIES; DENDRITIC CELLS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GLIOBLASTOMA; HLA-DR ANTIGENS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; LYMPHATIC SYSTEM; MALE; MIDDLE AGED; NEUROGLIA; RETROSPECTIVE STUDIES; SURVIVAL; TRANSCRIPTION FACTORS;

EID: 9444290731     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2004.00573.x     Document Type: Article

References (14)

1. Lassmann H, Reindl M, Rauschka H, Berger J, Aboul-Enein F, Berger T, Zurbriggen A, Lutterotti A, Bruck W, Weber JR, Ullrich R, Schmidbauer M, Jellinger K, Vandevelde M. A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions. Brain 2003; 126: 1347-57
2. Sondergaard KL, Hilton DA, Penney M, Ollerenshaw M, Demaine AG. Expression of hypoxia-inducible factor 1alpha in tumours of patients with glioblastoma. Neuropathol Appl Neurobiol 2002; 28: 210-17
3. Birner P, Piribauer M, Fischer I, Gatterbauer B, Marosi C, Ambras PF, Ambras IM, Bredel M, Oberhuber G, Rossler K, Budka H, Harris AL, Hainfellner JA. Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol Zurich, Switzerland 2003; 13: 133-43
4. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61: 215-25; discussion 226-9
5. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1985; 53: 457-81
6. Di Lorenzo N, Palma L, Nicole. S. Lymphocytic infiltration in long-survival glioblastomas: possible host's resistance. Acta Neurochir (Wien) 1977; 39: 27-33
7. Boker DK. et al. Mononuclear infiltrates in human intracranial tumors as a prognostic factor. Influence of preoperative steroid treatment. I. Glioblastoma. Clin Neuropathol 1984; 3: 143-7
8. Safdari H, Hochberg FH, Richardson EP Jr. Prognostic value of round cell (lymphocyte) infiltration in malignant gliomas. Surg Neurol 1985; 23: 221-6
9. Palma L, Di Lorenzo N, Guidetti B. Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. J Neurosurg 1978; 49: 854-61
10. Castro MG, Cowen R, Williamson IK, David A, Jimenez-Dalmaroni MJ, Yuan X, Bigliari A, Williams JC, Hu J, Lowenstein PR. Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther 2003; 98: 71-108
11. Andratschke N, Grosu AL, Molls M, Nieder C. Perspectives in the treatment of malignant gliomas in adults. Anticancer Res 2001; 21: 3541-50
12. Roth W, Weller. M. Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives. Cell Mol Life Sci 1999; 56: 481-506
13. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM, Black KL. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61: 842-7
14. Avigan D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev 1999; 13: 51-64